Health Canada approves Ultomiris for AChR-positive generalized myasthenia gravis
Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common type of MG-causing antibody
The announcement came less than a year after Ultomiris was approved for the condition in the U.S., and a couple of months after receiving similar approvals in Japan and Europe.
Ultomiris is designed to block the activation of the complement cascade, a group of inflammatory immune proteins whose activation plays a central role in this autoimmune attack. The treatment works in virtually the same way as the earlier-approved MG therapy Soliris (eculizumab), but it is designed to last longer in the body, allowing for less frequent infusions (every eight weeks instead of every two weeks). Both Ultomiris and Soliris were developed by Alexion, which is now a subsidiary of AstraZeneca.
Ultomiris is designed to block the activation of the complement cascade, a group of inflammatory immune proteins whose activation plays a central role in this autoimmune attack. The treatment works in virtually the same way as the earlier-approved MG therapy Soliris (eculizumab), but it’s designed to last longer in the body, allowing for less frequent infusions (every eight weeks instead of every two weeks). Both Ultomiris and Soliris were developed by Alexion, which is now a subsidiary of AstraZeneca.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins